Results 221 to 230 of about 119,519 (336)

Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis [PDF]

, 2017
Steve Chaplin
openalex   +1 more source

Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients

, 2022
Çiğdem Yüce Kahraman, Gülden Sincan, Abdülgani Tatar   +2 more
openalex   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Quaggetto M, Ben Salem T, Haroche J, Campagne J, Moyon Q, Lhote R, Amoura Z, Cohen Aubart F.   +7 more
europepmc   +1 more source

Histopathological Characterization and Differential Expression of miRNAs in Male Pediatric Patients With Lichen Sclerosus

Andrology, EarlyView.
ABSTRACT Background Lichen sclerosus is a chronic, inflammatory, scarring disease of the skin that manifests mostly in the genital region. Objective We studied the histomorphological characteristics, grade, and pattern of inflammation in male pediatric patients with lichen sclerosus.
Valerie Flammang, Arndt Hartmann, Robert Stöhr, Katrin Weigelt, Carol Geppert, Frederik A. Stuebs, Matthias W. Beckmann, Bernd Wullich, Helge Taubert, Marios Marcou, Sven Wach   +10 more
wiley   +1 more source

Progression of mycosis fungoides in a patient receiving a Janus kinase inhibitor. [PDF]

JAAD Case Rep
Stankiewicz JM, Kersten JM, Merkus VA, de Haan S, Jansen PM, Vermeer MH, Ottevanger R.   +6 more
europepmc   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Intraocular infections following biologicals and Janus Kinase inhibitors. [PDF]

Indian J Ophthalmol
Dutta Majumder P, Kene RD.
europepmc   +1 more source

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

British Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff, Roochi Trikha, Emma M. Groarke, Bhavisha A. Patel   +3 more
wiley   +1 more source

Janus Kinase Inhibitors as A Breakthrough Treatment for Refractory Dissecting Cellulitis of the Scalp. [PDF]

Eur J Case Rep Intern Med
Al-Mamoori A, Al-Badri SG, Sayed SBH, Al-Daraji W.   +3 more
europepmc   +1 more source